US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Alamar Biosciences

33.95

-0.2900-0.85%

Volume:70.55K

Turnover:2.38M

Market Cap:2.35B

PE:-47.42

High:34.50

Open:34.07

Low:33.18

Close:34.24

52wk High:38.54

52wk Low:18.85

Shares:69.31M

Float Shares:12.94M

Volume Ratio:0.35

T/O Rate:0.55%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7160

EPS(LYR):-2.5873

ROE:-33.57%

ROA:-13.53%

PB:7.52

PE(LYR):-13.12

Loading ...

Overview Company News Filings

U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis

Alamar Biosciences Q1 Loss Widens, Revenue Rises

MT Newswires Live

Earnings Flash (ALMR) Alamar Biosciences Posts Q1 Net Loss $1.74 a Share

MT Newswires Live

Alamar Biosciences Q1 FY26 net loss widens to $21.3 million; revenue rises 99% to $26 million

Alamar Biosciences Inc - Cash and Equivalents $69.5 Mln as of March 31, 2026

THOMSON REUTERS

Alamar Biosciences: Q1 EPS $-1.74

THOMSON REUTERS

Alamar Biosciences Inc - Q1 2026 Revenue Rises to $26.0 Mln

THOMSON REUTERS

Press Release: Alamar Biosciences Reports First Quarter 2026 Financial Results

Alamar Biosciences to present at BofA Securities 2026 Healthcare Conference

Biotech firm Odyssey targets $810 million valuation in US IPO

Alamar Biosciences Index Debut And Shelf Filing Reshape Investor Tradeoffs

Simply Wall St.

Alamar director Nicholas Naclerio reports acquisition of 235,294 common shares for $4 million

Alamar Biosciences adopts amended and restated bylaws ahead of IPO close

Stock Track | Alamar Biosciences Soars 5% Intraday Following Successful NASDAQ IPO Listing

Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ

Cathie Wood’s ARK Investment buys 537.5K shares of Alamar Biosciences today

Alamar Biosciences Makes Market Debut with Shares Surging Over 34%

Stock Track | Alamar Biosciences Soars 32.94% in Intraday Trading on Strong Nasdaq Debut After Upsized IPO

Alamar Biosciences Shares Open for Trading at $22.6 in Nasdaq Debut VS U.S. IPO Price of $17 Each

THOMSON REUTERS

BUZZ-Alamar Biosciences set to open above offer price in Nasdaq debut

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/ALMR/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ALMR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMR\",,,,,undefined,":{"symbol":"ALMR","market":"US","secType":"STK","nameCN":"Alamar Biosciences","latestPrice":33.95,"timestamp":1787592992168,"preClose":34.24,"halted":0,"volume":70549,"delay":0,"changeRate":-0.008469626168224274,"floatShares":12937500,"shares":69311200,"eps":-0.716,"marketStatus":"Trading","change":-0.29,"latestTime":"08-24 13:37:20 EDT","open":34.07,"high":34.5,"low":33.175,"amount":2382224.767197,"amplitude":0.038697,"askPrice":33.71,"askSize":188,"bidPrice":33.64,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-0.716,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":34.24,"preHourTrading":{"tag":"盘前","latestPrice":34.74,"preClose":34.24,"latestTime":"07:41 EDT","volume":20,"amount":691.1,"timestamp":1787571691393,"change":0.5,"changeRate":0.014603,"amplitude":0.067757},"postHourTrading":{"tag":"盘后","latestPrice":34,"preClose":34.24,"latestTime":"18:47 EDT","volume":2273,"amount":77688.05,"timestamp":1787352444838,"change":-0.24,"changeRate":-0.007009,"amplitude":0.007009},"volumeRatio":0.350983},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMR\",,,,,undefined,":{"symbol":"ALMR","floatShares":12937500,"roa":"-13.53%","roe":"-33.57%","lyrEps":-2.587299,"volumeRatio":0.350983,"shares":69311200,"dividePrice":0,"high":34.5,"amplitude":0.038697,"preClose":34.24,"low":33.175,"week52Low":18.845,"pbRate":"7.52","psRate":"23.43","week52High":38.54,"institutionHeld":0,"latestPrice":33.95,"committee":-0.948187,"eps":-0.716,"divideRate":0,"volume":70549,"delay":0,"ttmEps":-0.716,"open":34.07,"prevYearClose":17,"prevWeekClose":34.24,"prevMonthClose":25.36,"prevQuarterClose":27.09,"fiveDayClose":32.13,"twentyDayClose":24.4,"sixtyDayClose":19.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-10","symbol":"ALMR","fiscalQuarterEnding":"2026/06","expectedEps":-0.36,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786334400000,"reportTimeType":"post","actualEps":-0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.4,"hold":0.2,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4,"analysts":5,"updateTime":1779249600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMR","date":"2026-08-21","current":-46.836592,"percent":0.2,"low":-61.051551,"twenty":-48.403484,"median":-40.899736,"eighty":-33.37648,"high":-30.427746,"avg":-41.847808,"sd":8.117095,"marketCap":2403765414},"quantilePoints":[{"date":"2026-05-01","current":-57.277289,"twenty":-59.990183,"median":-57.277289,"eighty":-56.655108,"marketCap":1707951482},{"date":"2026-05-08","current":-54.120633,"twenty":-59.175857,"median":-56.408065,"eighty":-54.495772,"marketCap":1613823165},{"date":"2026-05-15","current":-35.878919,"twenty":-57.629553,"median":-54.669617,"eighty":-53.99338,"marketCap":1560194796},{"date":"2026-05-22","current":-35.066025,"twenty":-56.9113,"median":-54.440874,"eighty":-34.919385,"marketCap":1524846092},{"date":"2026-05-29","current":-31.495666,"twenty":-56.325717,"median":-53.802501,"eighty":-32.467951,"marketCap":1369589035},{"date":"2026-06-05","current":-34.253131,"twenty":-55.282649,"median":-35.878919,"eighty":-32.646469,"marketCap":1489497387},{"date":"2026-06-12","current":-35.368868,"twenty":-54.724515,"median":-34.699426,"eighty":-32.401007,"marketCap":1538015217},{"date":"2026-06-18","current":-32.196986,"twenty":-54.651317,"median":-34.308917,"eighty":-32.158732,"marketCap":1400085957},{"date":"2026-06-26","current":-42.828368,"twenty":-54.587269,"median":-35.066025,"eighty":-32.350002,"marketCap":1862391567},{"date":"2026-07-02","current":-41.648874,"twenty":-54.495772,"median":-35.368868,"eighty":-32.60184,"marketCap":1811101290},{"date":"2026-07-10","current":-42.206743,"twenty":-54.303628,"median":-36.436788,"eighty":-32.691099,"marketCap":1835360205},{"date":"2026-07-17","current":-39.76806,"twenty":-53.99338,"median":-39.098618,"eighty":-32.700662,"marketCap":1729314090},{"date":"2026-07-24","current":-41.266336,"twenty":-53.295956,"median":-39.903543,"eighty":-32.786733,"marketCap":1794466605},{"date":"2026-07-31","current":-39.959329,"twenty":-52.542305,"median":-39.576791,"eighty":-32.978002,"marketCap":1737631433},{"date":"2026-08-07","current":-44.788877,"twenty":-45.298929,"median":-40.039025,"eighty":-33.153333,"marketCap":1947644326},{"date":"2026-08-14","current":-46.000078,"twenty":-46.279543,"median":-40.206385,"eighty":-33.248967,"marketCap":2284409856},{"date":"2026-08-21","current":-48.403484,"twenty":-48.403484,"median":-40.899736,"eighty":-33.37648,"marketCap":2403765414}],"updateTime":1787584918119},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMR\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634298415","title":"U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis","url":"https://stock-news.laohu8.com/highlight/detail?id=2634298415","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634298415?lang=en_us&edition=fundamental","pubTime":"2026-05-12 15:21","pubTimestamp":1778570494,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Accuray, Aevex, ZoetisMay 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Accuray, Aevex and Zo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL4N41P0LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","ASTH","KKR","APO","ZTS","HIMY","SPG","PSIX","BK4216","FTV","ARES","GTM","BX","HIMS","CEVA","CYTK","SGI","CVS","AGM","TGT","BK4106","ARAY","HIMZ","LU2089985449.USD","LU0345781412.USD","LU2458330169.SGD","PLNT","SNDA","CE","ALMR","BAM","LU0476273544.USD","SIBN","AMAT","MOS","TRGP","CGNX","HMYY","LENZ","ELVN","TXG","WPC","HIYY","LQDA","VSNT","LU0106831901.USD","VCTR","AVEX","BILL","TOST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633456291","title":"Alamar Biosciences Q1 Loss Widens, Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2633456291","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633456291?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:28","pubTimestamp":1778243320,"startTime":"0","endTime":"0","summary":"Alamar Biosciences  reported a Q1 loss Friday of $1.74 per diluted share, widening from a loss of $0.68 a year earlier.Revenue for the quarter ended March 31 was $26 million, up from $13.1 million a year earlier.As of March 31, the company had cash, cash equivalents, and restricted cash of $69.5 million.Shares of the company were up 2.4% in Friday's premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633455171","title":"Earnings Flash (ALMR) Alamar Biosciences Posts Q1 Net Loss $1.74 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2633455171","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633455171?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:04","pubTimestamp":1778241871,"startTime":"0","endTime":"0","summary":"Earnings Flash (ALMR) Alamar Biosciences Posts Q1 Net Loss $1.74 a Share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633455458","title":"Alamar Biosciences Q1 FY26 net loss widens to $21.3 million; revenue rises 99% to $26 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633455458","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633455458?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:03","pubTimestamp":1778241795,"startTime":"0","endTime":"0","summary":"Alamar Biosciences posted Q1 revenue of USD 26 million, up 99% year over year.Net loss widened to USD 21.3 million; operating loss widened to USD 12.3 million.Gross margin rose to 56%, up 7 percentage points; operating expenses climbed 79% to USD 26.8 million on higher personnel costs, product-offering expansion, legal costs, accounting costs.Consumables revenue more than doubled to USD 14 million; instrument revenue rose 78% to USD 7.4 million.Raised about USD 220 million in gross IPO proceeds in April; plans to issue full-year 2026 revenue guidance with Q2 results in August.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL6KssWl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","SG9999014039.USD","SG9999014021.USD","BK4121","ALMR","SG9999014005.SGD","BK4585","LU2095319765.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","LU0314104364.USD","NDAQ","IE00BKPKM429.USD","LU2210149790.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633552064","title":"Alamar Biosciences Inc - Cash and Equivalents $69.5 Mln as of March 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633552064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633552064?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:00","pubTimestamp":1778241601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUABR7QKZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMR","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633455203","title":"Alamar Biosciences: Q1 EPS $-1.74","url":"https://stock-news.laohu8.com/highlight/detail?id=2633455203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633455203?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:00","pubTimestamp":1778241601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUABR7QKZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633201455","title":"Alamar Biosciences Inc - Q1 2026 Revenue Rises to $26.0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2633201455","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633201455?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:00","pubTimestamp":1778241601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUABR7QKZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633556264","title":"Press Release: Alamar Biosciences Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633556264","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633556264?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:00","pubTimestamp":1778241600,"startTime":"0","endTime":"0","summary":"FREMONT, Calif., May 08, 2026  -- Alamar Biosciences, Inc. , a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026.-- Generated $26.0 million of total revenue for the first quarter of 2026,an increase of 99% as compared to the corresponding period of 2025.-- Launched two new products, NULISAseq Neuro 220 Panel and. Operating expenses were $26.8 million for the first quarter of 2026, a 79% increase from $14.9 million for the corresponding prior-year period. The year-over-year increase in operating expenses was primarily related to increased personnel costs, increased costs related to expansion of our product offerings, and increased professional costs for legal and accounting services.Operating loss was $12.3 million for the first quarter of 2026, as compared to an operating loss of $8.6 million for the corresponding prior-year period. This includes $1.5 million of stock-based compe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR","BK4099","BK4588","BK4604","BK4121","03160","BK4555","TM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633262549","title":"Alamar Biosciences to present at BofA Securities 2026 Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633262549","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633262549?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:12","pubTimestamp":1778011930,"startTime":"0","endTime":"0","summary":"Alamar Biosciences to present at BofA Securities 2026 Healthcare Conference on May 12 in Las Vegas.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL7sc6YC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LU1366192091.USD","LU0648000940.SGD","IE00BKVL7J92.USD","LU0053666078.USD","IE00BN0W2V16.EUR","LU0106831901.USD","LU1880398471.USD","LU2095319765.USD","LU0640476718.USD","LU1718418525.SGD","ALMR","LU2210150020.SGD","BK4207","LU1894683348.USD","IE00BBT3K403.USD","LU2129689605.HKD","IE00B64PRP62.GBP","IE00BLSP4452.SGD","LU0256863811.USD","IE00B7SZLL34.SGD","LU0306806265.USD","LU0321505439.SGD","NDAQ","LU0310800965.SGD","BK4504","IE00BN0W2W23.USD","LU0234570918.USD","LU0098860793.USD","SG9999014013.SGD","LU0256863902.USD","LU0648001328.SGD","LU0052756011.USD","LU0971096721.USD","LU1496350171.SGD","LU0321505868.SGD","LU2129689514.USD","LU2265009873.SGD","LU0203345920.USD","LU0320765489.SGD","LU1894683264.USD","LU0170899867.USD","SG9999014021.USD","LU1883839398.USD","LU0417517546.SGD","LU1804176565.USD","BAC","LU0130518102.USD","IE00BZ1G4Q59.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632932017","title":"Biotech firm Odyssey targets $810 million valuation in US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2632932017","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632932017?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:48","pubTimestamp":1777891715,"startTime":"0","endTime":"0","summary":"UPDATE 2-Biotech firm Odyssey targets $810 million valuation in US IPOAdds details throughout. May 4  - Biopharmaceutical company Odyssey Therapeutics said on Monday it is targeting a valuation of up to $809.9 million in its initial public offering in the United States, as investors warm up to drug developers. The Boston-based company is seeking to raise up to $238.3 million by offering 13.2 million shares priced between $16 and $18 apiece. The U.S. IPO market has made a strong comeback in recent weeks, setting the stage for a pickup in listings in coming months.Last month, weight-loss drug developer Kailera Therapeutics KLRA.O, Alamar Biosciences ALMR.O and nuclear reactor maker X-Energy XE.O made stellar market debuts.April marked the biggest month for new filings in more than four years, according to Renaissance Capital, a provider of IPO-focused research and ETFs. This despite a volatile first quarter amid a sell-off in tech stocks, private credit strains and the Middle East confli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL4N41H0NW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["3NVD.UK","LU1934455277.USD","LU0345768740.USD","LU2420271590.USD","BK4533","NVDA","ANV","LU2552382132.HKD","NVIW.SI","NVDY","LU2756315664.SGD","NVDS","NVDD","DIPS","NVDW","SNVD.UK","IE000YTNTUN2.SGD","LU1989772923.USD","XE","NVD3.UK","NVD2.UK","LU0072462426.USD","NVDO","LU0061474705.USD","NVDB","NVDQ","NVDX","NVDL","LU0965509283.SGD","LU0265550359.USD","ALMR","LU0158827948.USD","NVII","2NVD.UK","LU1803068979.SGD","IE00B3SWFQ91.USD","NVDU","NVDS.UK","BK4532","LU0310799852.SGD","NVDG","LU0345768153.USD","LU1153585028.USD","SGXZ81514606.USD","SGXZ23171101.USD","LU0724617625.USD","KLRA","LU1267930490.SGD","NVD","LU2236285917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632650975","title":"Alamar Biosciences Index Debut And Shelf Filing Reshape Investor Tradeoffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2632650975","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632650975?lang=en_us&edition=fundamental","pubTime":"2026-05-01 01:05","pubTimestamp":1777568757,"startTime":"0","endTime":"0","summary":"Alamar Biosciences (NasdaqGS:ALMR) has been added to the NASDAQ Composite Index, increasing its visibility among index-tracking investors.\nThe company has also filed a new shelf registration, creating flexibility to raise capital in the future if management chooses.\nShares most recently closed at $24.48, with a year-to-date return of 11.3%.\n\nFor you as an investor, the NASDAQ Composite inclusion means Alamar Biosciences now sits on the radar of more funds that track or reference this index...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-almr/alamar-biosciences/news/alamar-biosciences-index-debut-and-shelf-filing-reshape-inve","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-almr/alamar-biosciences/news/alamar-biosciences-index-debut-and-shelf-filing-reshape-inve","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QLD","FTEC","QQQE","PSQ","TQQY","BK4121","NQmain","QQQA","TQQQ","ONEQ",".IXIC","MNQmain","JEPQ","NDX","QQQY","QDTE","NVIW.SI","QQQM","QYLG","ALMR","QID","QQQJ","QQQ","SQQQ","IYW","GPIQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629770819","title":"Alamar director Nicholas Naclerio reports acquisition of 235,294 common shares for $4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629770819","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629770819?lang=en_us&edition=fundamental","pubTime":"2026-04-21 08:32","pubTimestamp":1776731546,"startTime":"0","endTime":"0","summary":"Alamar Biosciences director Nicholas Naclerio reported a change in beneficial ownership tied to Illumina Innovation Fund II.Holdings shifted into 5,856,536 shares of common stock held indirectly.Illumina Innovation Fund III reported indirect ownership of 507,076 shares of common stock, including a purchase of 235,294 shares at USD 17.Naclerio also reported receipt of 5,686 restricted stock units.Form also showed a grant of 25,599 stock options with an exercise price of USD 17.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alamar Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL3pgBm9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Alamar director Nicholas Naclerio reports acquisition of 235,294 common shares for $4 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629577560","title":"Alamar Biosciences adopts amended and restated bylaws ahead of IPO close","url":"https://stock-news.laohu8.com/highlight/detail?id=2629577560","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629577560?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:04","pubTimestamp":1776715456,"startTime":"0","endTime":"0","summary":"Alamar Biosciences adopted amended and restated bylaws effective April 20, 2026 in connection with IPO closing.Board and stockholders had authorized bylaw changes to take effect immediately prior to IPO close.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alamar Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL358Qhm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115536918","title":"Stock Track | Alamar Biosciences Soars 5% Intraday Following Successful NASDAQ IPO Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=1115536918","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115536918?lang=en_us&edition=fundamental","pubTime":"2026-04-20 22:16","pubTimestamp":1776694619,"startTime":"0","endTime":"0","summary":"Alamar Biosciences (ALMR) saw its stock price soar by 5.00% during intraday trading on Monday, reflecting strong investor interest in the newly listed company.The surge follows the company's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628871890","title":"Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ","url":"https://stock-news.laohu8.com/highlight/detail?id=2628871890","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628871890?lang=en_us&edition=fundamental","pubTime":"2026-04-20 10:36","pubTimestamp":1776652560,"startTime":"0","endTime":"0","summary":"Qiming Venture Partners led Alamar's Series A financing in 2020 and continued to fund the company's development in the following Series B and Series C rounds. Before the company's IPO, Qiming Venture Partners held approximately 19.2% stake in Alamar and was one of its most important institutional investors.Founded in 2018, Alamar is a commercial-stage proteomics company dedicated to developing and commercializing proteomics technologies and establishing the gold standard in protein detection and analysis. Alamar's self-developed NULISA technology breaks through the design limitations of existing proteomics tools, delivering ultra-high sensitivity, high specificity, flexible multiplex protein detection, broad dynamic range and seamless automation to detect protein biomarkers at extremely low concentrations, filling a critical gap previously uncovered by other protein detection methods.Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfol","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/precision-proteomics-leader-alamar-biosciences-lists-on-nasdaq-302746795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIW.SI","MNQmain","QDTE","BK6062","SG9999008742.SGD","NQmain","QLD","JEPQ",".IXIC","QQQJ","SG9999014492.USD","V03.SI","SQQQ","QQQA","QID","SG9999001135.SGD","TQQY","QYLG","SG9999006266.SGD","QQQM","FTEC","TQQQ","PSQ","SG9999004220.SGD","SG9999014484.SGD","SG9999000475.SGD","QQQE","SG9999001846.SGD","ALMR","ONEQ","QQQY","SG9999004360.SGD","QQQ","NDX","BK6515","GPIQ","IYW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628073845","title":"Cathie Wood’s ARK Investment buys 537.5K shares of Alamar Biosciences today","url":"https://stock-news.laohu8.com/highlight/detail?id=2628073845","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628073845?lang=en_us&edition=fundamental","pubTime":"2026-04-18 08:10","pubTimestamp":1776471012,"startTime":"0","endTime":"0","summary":"20:08 EDT Cathie Wood’s ARK Investment buys 537.5K shares of Alamar Biosciences (ALMR) today Published first on TheFly – the ultimate source for re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-537-5k-shares-of-alamar-biosciences-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-537-5k-shares-of-alamar-biosciences-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKX","SARK","ARKW","ARKG","ARKF","BK4585","BK4544","BK4588","ARKK","ARKQ","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111071379","title":"Alamar Biosciences Makes Market Debut with Shares Surging Over 34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111071379","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111071379?lang=en_us&edition=fundamental","pubTime":"2026-04-18 00:38","pubTimestamp":1776443894,"startTime":"0","endTime":"0","summary":"Alamar Biosciences (ALMR.US) began trading on the U.S. stock market on Friday, with its share price opening more than 34% higher at $22.91. The IPO price was set at $17 per share. Alamar Biosciences...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176686851","title":"Stock Track | Alamar Biosciences Soars 32.94% in Intraday Trading on Strong Nasdaq Debut After Upsized IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1176686851","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176686851?lang=en_us&edition=fundamental","pubTime":"2026-04-18 00:37","pubTimestamp":1776443855,"startTime":"0","endTime":"0","summary":"Alamar Biosciences (ALMR) stock soared 32.94% during intraday trading on Friday, following its initial public offering on the Nasdaq.The proteomics company, which develops instruments to detect...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628783958","title":"Alamar Biosciences Shares Open for Trading at $22.6 in Nasdaq Debut VS U.S. IPO Price of $17 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2628783958","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628783958?lang=en_us&edition=fundamental","pubTime":"2026-04-18 00:34","pubTimestamp":1776443685,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nL4N41016L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628195788","title":"BUZZ-Alamar Biosciences set to open above offer price in Nasdaq debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2628195788","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628195788?lang=en_us&edition=fundamental","pubTime":"2026-04-17 23:57","pubTimestamp":1776441459,"startTime":"0","endTime":"0","summary":"BUZZ-Alamar Biosciences set to open above offer price in Nasdaq debut** Protein biomarker detection platform Alamar Biosciences ALMR.O on track to open above offer price in Nasdaq debut** Stock recently indicated to open at $22.50 apiece versus $17 offer price** Fremont, California-based ALMR sold about 11.3 million shares in an upsized IPO at top end of $15-$17 marketed range to raise $191.3 million** Proteomics firm develops instruments to detect low-level protein biomarkers in blood, enabling disease research and diagnostics** J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners and Stifel acted as joint book-running managers for offering  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nL6N410108:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314106906.USD","BAC","LU0070302665.USD","LU0130517989.USD","LU0234570918.USD","IE0002270589.USD","IE00B1BXHZ80.USD","LU0640476718.USD","LU0648001328.SGD","LU0980610538.SGD","LU1880398554.USD","LU1035773651.USD","LU2129689431.USD","LU0417517546.SGD","SF","LU1496350171.SGD","LU2129689605.HKD","IE0001KFT4U8.USD","LU1280957306.USD","LU0170899867.USD","LU0477156797.USD","LU2133065610.SGD","LU0477156953.USD","LU0320765646.SGD","IE00B7SZLL34.SGD","LU0053666078.USD","LU0203347892.USD","LU0787776722.HKD","LU1074936037.SGD","LU1506573853.SGD","LU1791807156.HKD","LU0321505868.SGD","IE00BKVL7J92.USD","LU1804176565.USD","IE00BLSP4452.SGD","LU1366192091.USD","IE00B19Z3B42.SGD","BK4588","MNSH","LU1883839398.USD","ALMR","LU2129689514.USD","MDIT","IE00BLSP4239.USD","LU0320765489.SGD","LU0130518102.USD","LU2265009873.SGD","LU0256863902.USD","LU0321505439.SGD","LU1496350502.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":63,"code":"91000000","status":"200"}]}}